09 April 2024: Original Paper
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study
Atif S. Siddiqui 12ABCDEF* , Jawairia Shakil 23CDEFDOI: 10.12659/AOT.943652
Ann Transplant 2024; 29:e943652
Table 1 Baseline demographics and clinical characteristics.
| Total(N=232) | No transfusion(n=74) | Any transfusion(n=158) | p-value | |
|---|---|---|---|---|
| Age at transplant (years), median (IQR) | 62.0 (53.5, 66.0) | 64.0 (59.0, 67.6) | 60.3 (51.0, 65.0) | |
| Gender | 0.02 | |||
| Female | 105 (45.3) | 25 (33.8) | 80 (50.6) | |
| Male | 127 (54.7) | 49 (66.2) | 78 (49.4) | |
| Ethnicity | 0.004 | |||
| White | 152 (65.5) | 58 (78.4) | 94 (59.5) | |
| Black | 44 (19.0) | 5 (6.8) | 39 (24.7) | |
| Hispanic/Latino | 28 (12.1) | 7 (9.5) | 21 (13.3) | |
| Asian | 8 (3.4) | 4 (5.4) | 4 (2.5) | |
| Body mass index at transplant, median (IQR) | 27.3 (23.2, 30.6) | 29.0 (25.0, 31.6) | 26.3 (22.0, 30.2) | |
| Lung transplant type | ||||
| Single lung | 61 (26.3) | 37 (50.0) | 24 (15.2) | |
| Double lung | 171 (73.7) | 37 (50.0) | 134 (84.8) | |
| Primary diagnosis | 0.02 | |||
| Chronic obstructive pulmonary disease (COPD) | 52 (22.4) | 24 (32.4) | 28 (17.7) | |
| Cystic fibrosis | 9 (3.9) | 0 (0.0) | 9 (5.7) | |
| Interstitial lung disease (ILD) | 146 (62.9) | 44 (59.5) | 102 (64.6) | |
| Other | 25 (10.8) | 6 (8.1) | 19 (12.0) | |
| Previous malignancy | 0.02 | |||
| No | 219 (94.4) | 66 (89.2) | 153 (96.8) | |
| Yes6 | 13 (5.6) | 8 (10.8) | 5 (3.2) | |
| Diabetes | 0.60 | |||
| No | 164 (70.7) | 54 (73.0) | 110 (69.6) | |
| Yes | 68 (29.3) | 20 (27.0) | 48 (30.4) | |
| History of smoking | ||||
| No | 98 (42.2) | 19 (25.7) | 79 (50.0) | |
| Yes | 134 (57.8) | 55 (74.3) | 79 (50.0) | |
| Months in wait list, median (IQR) | 1.7 (0.5, 4.3) | 1.9 (0.9, 4.3) | 1.7 (0.4, 4.1) | 0.16 |
| Total serum bilirubin (mg/dL), median (IQR) | 0.3 (0.2, 0.5) | 0.3 (0.3, 0.5) | 0.3 (0.2, 0.5) | 0.28 |
| Serum creatinine at transplant, median (IQR) | 0.8 (0.7, 1.0) | 0.8 (0.7, 1.0) | 0.8 (0.7, 1.0) | 0.20 |
| eGFR at transplant (mL/mn/1.73 m), median (IQR) | 91.6 (74.5, 101.7) | 89.4 (68.6, 96.4) | 92.4 (76.8, 105.5) | 0.03 |
| eGFR at transplant (mL/mn/1.73 m) | 0.99 | |||
| ≥60 | 207 (89.2) | 66 (89.2) | 141 (89.2) | |
| 25 (10.8) | 8 (10.8) | 17 (10.8) | ||
| Any pre-transplant ECMO | 0.07 | |||
| No | 225 (97.0) | 74 (100.0) | 151 (95.6) | |
| Yes | 7 (3.0) | 0 (0.0) | 7 (4.4) | |
| Pre-transplant ventilation | 0.04 | |||
| No | 223 (96.1) | 74 (100.0) | 149 (94.3) | |
| Yes | 9 (3.9) | 0 (0.0) | 9 (5.7) | |
| Systolic PA pressure at transplant (mmHg), median (IQR) | 36.0 (30.0, 48.0) | 35.0 (30.0, 42.0) | 39.5 (32.0, 52.0) | 0.01 |
| Diastolic PA pressure at transplant (mmHg), median (IQR) | 16.0 (12.0, 20.0) | 15.5 (11.0, 20.0) | 17.0 (12.0, 22.0) | 0.16 |
| Mean PA pressure at transplant (mmHg), median (IQR) | 23.0 (18.0, 30.0) | 21.5 (17.0, 28.0) | 24.0 (18.0, 33.0) | 0.01 |
| Mean PCWP (mmHg), median (IQR) | 10.0 (6.0, 13.0) | 10.0 (7.0, 14.0) | 10.0 (6.0, 12.0) | 0.43 |
| Recipient CMV | 0.12 | |||
| Negative | 69 (29.7) | 27 (36.5) | 42 (26.6) | |
| Positive | 163 (70.3) | 47 (63.5) | 116 (73.4) | |
| CMV high risk (D+/R−) | 0.14 | |||
| No | 180 (77.6) | 53 (71.6) | 127 (80.4) | |
| Yes | 52 (22.4) | 21 (28.4) | 31 (19.6) | |
| HLA mismatch, median (IQR) | 5.0 (4.0, 6.0) | 5.0 (4.0, 5.0) | 5.0 (4.0, 6.0) | 0.79 |
| HLA mismatch ≥5 | 0.81 | |||
| No | 81 (35.8) | 25 (34.7) | 56 (36.4) | |
| Yes | 145 (64.2) | 47 (65.3) | 98 (63.6) | |
| Donor age (years), median (IQR) | 31.0 (22.0, 42.0) | 29.0 (23.0, 43.0) | 32.0 (21.0, 42.0) | 0.93 |
| Donor gender | 0.43 | |||
| Female | 106 (45.7) | 31 (41.9) | 75 (47.5) | |
| Male | 126 (54.3) | 43 (58.1) | 83 (52.5) | |
| Donor race/ethnicity | 0.08 | |||
| White | 101 (43.5) | 29 (39.2) | 72 (45.6) | |
| Black | 53 (22.8) | 19 (25.7) | 34 (21.5) | |
| Hispanic | 70 (30.2) | 20 (27.0) | 50 (31.6) | |
| Asian | 7 (3.0) | 5 (6.8) | 2 (1.3) | |
| Other | 1 (0.4) | 1 (1.4) | 0 (0.0) | |
| Donor body mass index, median (IQR) | 26.0 (22.6, 30.1) | 24.7 (22.1, 29.8) | 26.5 (23.5, 30.1) | 0.08 |
| Donor history of hypertension | 0.24 | |||
| No | 177 (76.3) | 60 (81.1) | 117 (74.1) | |
| Yes | 55 (23.7) | 14 (18.9) | 41 (25.9) | |
| Donor history of diabetes | 0.59 | |||
| No | 213 (91.8) | 69 (93.2) | 144 (91.1) | |
| Yes | 19 (8.2) | 5 (6.8) | 14 (8.9) | |
| Donor history of smoking | 0.26 | |||
| No | 215 (94.7) | 69 (97.2) | 146 (93.6) | |
| Yes | 12 (5.3) | 2 (2.8) | 10 (6.4) | |
| Ischemic time (hours), median (IQR) | 4.0 (3.3, 4.8) | 3.8 (3.0, 4.5) | 4.3 (3.5, 5.1) | |
| Values are in number and% unless otherwise specified; IQR – interquartile range; eGFR – estimated glomerular filtration rate; PA – pulmonary artery; PCWP – pulmonary capillary wedge pressure; CMV – Cytomegalovirus; HLA – human leukocyte antigen. | ||||